JP2023505206A5 - - Google Patents
Info
- Publication number
- JP2023505206A5 JP2023505206A5 JP2022533373A JP2022533373A JP2023505206A5 JP 2023505206 A5 JP2023505206 A5 JP 2023505206A5 JP 2022533373 A JP2022533373 A JP 2022533373A JP 2022533373 A JP2022533373 A JP 2022533373A JP 2023505206 A5 JP2023505206 A5 JP 2023505206A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- derived
- immune cells
- receptor
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945040P | 2019-12-06 | 2019-12-06 | |
| US62/945,040 | 2019-12-06 | ||
| PCT/US2020/063457 WO2021113744A1 (en) | 2019-12-06 | 2020-12-04 | Enhancement of ipsc-derived effector immune cell using small compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023505206A JP2023505206A (ja) | 2023-02-08 |
| JP2023505206A5 true JP2023505206A5 (https=) | 2023-12-11 |
Family
ID=76221001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533373A Pending JP2023505206A (ja) | 2019-12-06 | 2020-12-04 | 小化合物を使用するｉＰＳＣ由来エフェクター免疫細胞の増強 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230016034A1 (https=) |
| EP (1) | EP4069827A4 (https=) |
| JP (1) | JP2023505206A (https=) |
| KR (1) | KR20220124179A (https=) |
| CN (1) | CN115087731A (https=) |
| AU (1) | AU2020395239A1 (https=) |
| BR (1) | BR112022011072A2 (https=) |
| CA (1) | CA3160423A1 (https=) |
| IL (1) | IL293564A (https=) |
| MX (1) | MX2022006725A (https=) |
| WO (1) | WO2021113744A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2022011065A1 (en) * | 2020-07-07 | 2022-01-13 | The Nemours Foundation | Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer |
| AR125851A1 (es) * | 2021-05-12 | 2023-08-16 | Crispr Therapeutics Ag | Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas |
| WO2022269393A1 (en) * | 2021-06-23 | 2022-12-29 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
| AU2022304599A1 (en) * | 2021-07-02 | 2024-01-18 | Fate Therapeutics, Inc. | Protected effector cells and use thereof for allogeneic adoptive cell therapies |
| KR20240102994A (ko) * | 2021-11-08 | 2024-07-03 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양의 유비쿼터스 표적화를 향상시키는 조작된 이펙터 세포 및 방법 |
| TW202340453A (zh) * | 2022-01-28 | 2023-10-16 | 中國大陸商杭州啟函生物科技有限公司 | 用於基於細胞的免疫療法的方法和組合物 |
| US20250222029A1 (en) | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| US20250228943A1 (en) * | 2022-04-08 | 2025-07-17 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
| WO2024097911A1 (en) * | 2022-11-02 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting gprc5d |
| WO2024102704A2 (en) * | 2022-11-07 | 2024-05-16 | Fate Therapeutics, Inc. | Ipsc-derived nk cell targeting mica/b for solid tumor treatment |
| WO2025104248A1 (en) * | 2023-11-17 | 2025-05-22 | Repairon Immuno Gmbh | Method of producing an immune cell devoid of endogenous effector functions from pluripotent stem cells |
| CN117305241B (zh) * | 2023-11-28 | 2024-03-19 | 上海兴瑞一达生物科技有限公司 | 一种hiPSCs诱导分化为NK细胞的方法 |
| WO2025217183A1 (en) * | 2024-04-09 | 2025-10-16 | Board Of Regents, The University Of Texas System | Prepared natural killer cells and uses thereof |
| CN119220607B (zh) * | 2024-12-03 | 2025-03-07 | 星奕昂(上海)生物科技有限公司 | 编辑tim3基因获得功能强化的car-nk细胞的方法与应用 |
| CN121472143B (zh) * | 2026-01-06 | 2026-03-31 | 南京医拓生物科技有限公司 | 高活化状态nk细胞富集型淋巴细胞的培养方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2992551A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| WO2017025323A1 (en) * | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
| KR20250141836A (ko) * | 2015-11-04 | 2025-09-29 | 페이트 세러퓨틱스, 인코포레이티드 | 만능 세포의 유전자 조작 |
| JP7653759B2 (ja) * | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| US20190037831A1 (en) * | 2016-02-01 | 2019-02-07 | Green Cross Lab Cell Corporation | Medium composition for cryopreservation of cell and use thereof |
| CN118948892A (zh) * | 2017-05-01 | 2024-11-15 | 朱诺治疗学股份有限公司 | 细胞疗法与免疫调节化合物的组合 |
| JP2020528885A (ja) * | 2017-07-19 | 2020-10-01 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2021505131A (ja) * | 2017-12-08 | 2021-02-18 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 |
| TW202020145A (zh) * | 2018-07-13 | 2020-06-01 | 國立大學法人京都大學 | γδＴ細胞的製造方法 |
-
2020
- 2020-12-04 US US17/782,600 patent/US20230016034A1/en active Pending
- 2020-12-04 AU AU2020395239A patent/AU2020395239A1/en active Pending
- 2020-12-04 JP JP2022533373A patent/JP2023505206A/ja active Pending
- 2020-12-04 IL IL293564A patent/IL293564A/en unknown
- 2020-12-04 EP EP20896968.3A patent/EP4069827A4/en active Pending
- 2020-12-04 KR KR1020227023102A patent/KR20220124179A/ko active Pending
- 2020-12-04 MX MX2022006725A patent/MX2022006725A/es unknown
- 2020-12-04 CA CA3160423A patent/CA3160423A1/en active Pending
- 2020-12-04 CN CN202080095636.2A patent/CN115087731A/zh active Pending
- 2020-12-04 BR BR112022011072A patent/BR112022011072A2/pt unknown
- 2020-12-04 WO PCT/US2020/063457 patent/WO2021113744A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023505206A5 (https=) | ||
| JP2022541441A5 (https=) | ||
| JP2022550899A5 (https=) | ||
| JP2022548943A5 (https=) | ||
| JP2022510207A5 (https=) | ||
| JP2021505131A5 (https=) | ||
| KR102618231B1 (ko) | 변형된 만능성 줄기 세포, 및 제조 및 사용 방법 | |
| KR102600544B1 (ko) | 트랜스진 유전자 태그 및 사용 방법 | |
| JP2024062986A (ja) | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 | |
| JP2023548467A5 (https=) | ||
| JP2023530704A5 (https=) | ||
| Maher | Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells | |
| CA3107675A1 (en) | Improving the efficacy and safety of adoptive cellular therapies | |
| US11458168B2 (en) | NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same | |
| JP2021519061A5 (https=) | ||
| JP2023548829A5 (https=) | ||
| JP2023549098A5 (https=) | ||
| RS62870B1 (sr) | Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe | |
| KR20180021137A (ko) | 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법 | |
| JP2024502157A (ja) | 樹状細胞活性化キメラ抗原受容体及びその使用 | |
| JP2023029624A (ja) | ｓｔｒｅｐタグ特異的キメラ受容体およびその使用 | |
| JP2023545992A5 (https=) | ||
| EP3805366A1 (en) | Improved t-cell therapy method | |
| JP2024515920A5 (https=) | ||
| JP7701453B2 (ja) | 固形腫瘍標的化骨格を有する細胞及びその使用 |